Products
Daclizumab Beta Biosimilar Monoclonal Antibody (CD25) for Research
Anti-IL2RA therapeutic antibody (Pre-made Daclizumab Beta biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-789-1mg | 1mg | 3090 |
| GMP-Bios-INN-789-10mg | 10mg | |
| GMP-Bios-INN-789-100mg | 100mg | |
| GMP-Bios-INN-789-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Daclizumab Beta Biosimilar, Whole Mab, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody |
| INN Name | Daclizumab Beta |
| Target | IL2RA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | 0 |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - IL2RA
1. Protein Interleukin-2 receptor subunit alpha
2. Gene IL2RA
3. Organism Homo sapiens (Human)
Function
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
